Prior to this, the controlling shareholder of WuXi Biological conducted the third placement reduction in the year.
On May 26, WuXi Biotech (02269.HK) opened up 1.98% to HK $ 129.0. The stock price has increased 30.77% year-to-date, WuXi Biotech ’s latest The total market value is 1678.41 HK $ 100 million.
After undergoing a substantial reduction in the company ’s controlling shareholders, WuXi Biotechnology has finally got good news of being increased by institutional shareholders.
On May 25, information from the Stock Exchange showed that The Capital Group Companics increased its holdings of 19.934 million shares of WuXi Biotechnology on May 21. The average price per share was HK $ 128.9689, involving HK $ 2.571 billion. After the increase, U.S. Capital held 5.32% of WuXi Biotech.
Pictures come from Ease of Disclosure
Since this year, American Capital Group has frequently shot in the Hong Kong stocks pharmaceutical sector. It has previously increased its shareholding in vaccine stocks Kang Xinuo Bio-B (06185.HK). As of May 19, The share ratio rose to 16.02%. This is the increase in the holdings of WuXi Biologics by the US capital group during the year.
According to information from the Stock Exchange, on the day before U.S. Capital Group increased its holdings, WuXi Biotech ’s controlling shareholder undertook the third placement reduction during the year.
According to the announcement, WuXi Biologics Holdings Limited intends to place 60 million existing shares at a price of HK $ 127.18 per share. Upon completion of the placing, Biologics Holdings ’shareholding ratio will be reduced to 26.89% and it will no longer be a controlling shareholder of WuXi shareholder.
After the announcement, WuXi Biotech opened lower by nearly 3% on May 21 and closed down by 0.52%.